2029 financial targets introduced and positive.

CHF500m additional capex: massive demand from clients for GLP1.

Offer by Samsung Biologics in cash with a 6% premium only.

Apollo reaches deal with board at 715p per share.

Potential disposal of Eastern Europe business.

The US struck 80 sites in Iran and revoked Iran's general license to sell oil.